How some private equity interests are negatively impacting rural communities; drugmakers invest heavily…in their shareholders; analysis shows broad coverage of insulin products in Medicare Part D; and, clinical waste drives excess healthcare spending.
The majority of hospitals fail to comply with price transparency rules; new prescription drugs come with increasingly higher price tags; the No Surprises Act has already prevented millions of surprise medical bills; and, private equity interests continue to exact a heavy toll on our healthcare system.
Pharmacy Benefit Managers, or PBMs, work for YOU to connect you with the right medicine, at the right time and at the right price.
A new study reinforces the link between hospital prices and market share; unnecessary care is found to have persisted during the pandemic; stakeholders continue to urge for full implementation of consumer surprise medical billing protections; and, Medicare spending on prescription drugs outpaces R&D costs.
Hospitals look to historic rate increases to cover their costs; millions threatened with loss of coverage after the public health emergency ends; a reminder that drugmakers are ultimately the ones responsible for controlling insulin costs; and, stakeholders continue to defend the Medicare Advantage program.
A new report shines a light on hospital drug errors; elsewhere, trends point to broad geographic variation in hospital pricing; stakeholders rally to the defense of the critical Medicare Advantage program; and, a look at how Big Pharma exploits the patent system to its own benefit.
Access for Maine consumers threatened by hospital system; the Administration appeals a surprise medical billing court ruling; private equity continues to exert pressure on our healthcare delivery model; and, a look at how access to Medicaid impacts health equity.
An important milestone is reached for new consumer surprise medical billing protections; proposed changes to Medicare Advantage are finalized; a new study takes a look at nonprofit hospitals’ charity care; and, rising drug prices continue to leave vulnerable populations exposed.
An important milestone is reached for new consumer surprise medical billing protections; proposed changes to Medicare Advantage are finalized; a new study takes a look at nonprofit hospitals’ charity care; and, rising drug prices continue to leave vulnerable populations exposed.
Premiums in Medicare Part D plans that cap insulin costs are higher than those that don’t; audio-only telehealth continues to play a critical role in connecting patients to care; unexpected medical bills rank amongst consumers’ biggest financial worries; and, new projections provide insights into where our healthcare spending might be headed.